All the premium content at PrimeInvestor

Paid subscribers can read timely, actionable recommendations from our experts!
A PrimeInvestor subscription gets you not just invaluable recommendations, rankings, and review tools. It keeps you up-to-date with the latest from the financial marketplace and tells you what you should be doing right now!
glenmark life sciences, glenmark life sciences ipo, IPO review
Categories

IPO Review: Glenmark Life Sciences – Should you invest?

Glenmark Life Sciences (GLS) is a generic API (Active Pharmaceutical Ingredients) manufacturer and a subsidiary of Glenmark Pharmaceuticals. The Glenmark Life Sciences IPO is worth Rs. 1,514 crore, comprising fresh issue of Rs.1,060 crore and an offer for sale worth Rs.454 crore by Glenmark Pharmaceuticals. Should you invest in the IPO of this high-value, non-commoditized API player?

Read More »
evaluate banking and finance stocks
Investment basics

How to evaluate banking and finance stocks

There are certain characteristics which make evaluating banking and finance stocks different from others which produce goods and services. Money cannot be lent to someone unless there is an inflow by way of capital or debt. Since it is not practical to lend only from capital, borrowing (or leverage) is the sustaining food for this business. Naturally in using this leverage, there are good and bad apples.

Premium article available only to subscribers.

Read More »
mid-and-smallcap index
Categories

Can the rally continue in the mid-and-smallcap index?

While the benchmark Nifty 50 index has been confined to a broad trading range, the broader markets or the mid-cap and small-cap universe has been buzzing with action. Let us take a closer look at the current trend and the near-term outlook for the Nifty MidSmallcap 400 Index. We have covered this index in an earlier article, and we take a relook now.

Premium article available only to subscribers.

Read More »
changes in prime funds
Categories

Quarterly review – changes in Prime Funds, our mutual fund recommendations

We are living in strange times. No, I am not talking of Covid-19. Your one-year returns of equity funds (across categories), at an average 31% between January to March 22, 2021, zoomed to an average 69% since March 23, 2021. In other words, 1-year returns suddenly doubled from March 23, 2021. If you recall, March 23 2020 was a market low. So, 1-year returns from March 23, 2021, have started looking abnormally high.

Premium article available only to subscribers.

Read More »
zomato ipo, ipo review, zomato
Categories

IPO Review : Zomato IPO – Invest or avoid?

If there’s talk in the stock markets today, it’s devoted to the upcoming Zomato IPO, which aims to mop up Rs 9,375 crore. Unlike the crop of recent private equity investor backed companies doing IPOs, this isn’t primarily an offer for sale. Zomato gets a whopping Rs 9,000 crore to deploy into its business mainly through a fresh issue of shares. Only one investor, Info Edge, will offload a Rs 375 crore stake. At the upper end of the price band of Rs 72-76, the post-offer market cap of listed Zomato will be around Rs 60,000 crore.

Premium article available only to subscribers.

Read More »
Login to your account
OR